The following milestones mark important progress in the consolidated federal litigation: Increased evidentiary standards for gastroparesis claims: Courts require plaintiffs alleging gastroparesis to support claims with objective gastric-emptying tests rather than symptoms alone, raising the bar for admissible medical evidence Daubert hearings on expert testimony: May 2025 hearings will determine whether plaintiffs medical experts can testify about causation potentially decisive rulings that could strengthen or weaken thousands of claims Short-form complaint process adoption: MDL implemented streamlined filing procedures to manage the influx of new cases efficiently while maintaining procedural fairness Monthly status conferences throughout 2025: Regular court meetings ensure ongoing case management and coordination as parties work through challenging scientific and legal issues In September 2025, Judge Marston allowed most plaintiffs claims to proceed after denying defendants motions to dismiss, including accusations that drugmakers failed to warn about gastrointestinal issues and misrepresented safety
Patients with excess weight but not obesity might still meet the criteria if they have a related medical issue
In the central nervous system, GLP-1Rs are located in numerous regions and it is suggested that GLP-1RAs act to promote weight loss through distributed effects rather than a specific or localized response [41]
But despite its initial success, Fen-Phen was soon associated with serious adverse health effects
Arbutus holds many patents relating to LNP-nucleic acid formulations generally, with the LNPs defined by ratios of the lipids in the particles
Onglyza is used for glycemic control in patients with type 2 diabetes mellitus
